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Lately, oncolytic viruses have been used to mitigate cancer as they lyse tumor cells whilst
leaving normal cells largely unharmed (as opposed to many other forms of cancer treat-
ment). The oncolytic effect depends on both viral replication ability and immune re-
sponse type induced by said replication. A major challenge posed by this therapy is any
potential delay that can occur during viral replication, combined with a fast immune re-
sponse. For this project, we will investigate possible trade-offs of the interactions, with
particular focus on the effect(s) of delay.We will extend recently published mathematical
models on virotherapy by taking into account the simultaneous effect of the delay and
considering various forms of virus-cell infections. We perform stability analysis with




how well this model would fit data or whether by the introduction of the delay terms,
we improve the fit of the data. Eventually, we derive an explicit formula for the trade-off
between the two delays that leads to tumor eradication. One of the main findings is the
occurrence of a delay-induced Hopf bifurcation, indicative of tumor relapse which is a
confirmation of other previous cancer virotherapy mathematical models.
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Abstract
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Onkolitiese virusse word die afgelope tyd gebruik om kanker te versag, aangesien hulle 
tumorselle lig, terwyl normale selle grootliks ongedeerd bly (in teenstelling met baie ander 
vorme van kankerbehandeling). Die onkolitiese effek is afhanklik van sowel die virale 
replikasievermoë as die immuun-re-sponse tipe wat deur genoemde replikasie veroorsaak word. 
'n Groot uitdaging wat hierdie terapie inhou, is die potensiële vertraging wat tydens 
virusreplikasie kan voorkom, gekombineer met 'n vinnige immuunreaksie. Vir hierdie projek 
ondersoek ons  moontlike inruilings van die interaksies, veral met die oog op die gevolge van 
vertraging. Ons brei wiskundige modelle oor viroterapie wat onlangs gepubliseer is, uit deur die 
gelyktydige effek van die vertraging en die oorweging van verskillende vorme van 
virusselinfeksies in ag te neem. Ons doen stabiliteitsanalise met die vertraging en voer 
numeriese simulasies uit om die wiskundige bevindings te bevestig en te bepaal hoe goed 
hierdie model by die data sou pas, of deur die inwerkingtreding van die vertragingsterme die pas 
van die data te verbeter. Uiteindelik verkry ons 'n eksplisiete formule vir die verhandeling tussen 
die twee vertragings wat lei tot die uitwissing van gewasse. Een van die belangrikste bevindings 
is die voorkoms van 'n vertraging-geïnduseerde Hopf-bifurkasie, wat 'n aanduiding is van tumor-
terugval, wat die bevestiging is van ander vorige wiskundige modelle vir kankerviroterapie.
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Cancerous ailments have become a major cause of death world over in recent years.
(Sudhakar, 2009).
According to statistics by bodies such as GLOBOCAN (International agency for research
on Cancer, 2018), last year, almost 2 million new victims came from the USA. Almost half
of these cases projected to result in death (Siegel et al., 2017). We can therefore deduce
that this epidemic requires keen interest has to be taken to alleviate this problem (Danaei
et al., 2005).
There has been advancement in research and medicine to mitigate its effects and min-
imise the cases of cancer victims since its discovery in ancient Egypt around 1500 BC
when only palliative treatment was offered. In (Sajid et al., 2008; Saunders, 1991),the
authors describe this as just general taking care of a seriously ill patient who cannot be
cured.
Cancer has still persisted especially in recent years and has been attributed to lifestyle
habits such as smocking of tobacco which has been said to cause lung cancer (Sajid
et al., 2008). Other cancers can be caused by chemical carcinogens, radiation or viruses.
Cancer may also be hereditary.
Moreover, genes play a huge role in how cancer occurs. There are two main types of
genes: a) Oncogenes, which facilitate abnormal growth of otherwise normal cells to
1
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form tumors through mutations of prorooncogenes which control the frequency of cell
division and differentiation degree and b) Tumor suppressor genes which control cell
division and cell death. Once these genes malfunction, they cause an abnormal growth
in normal cells causing cancer (Sudhakar, 2009).
There are a couple of methods for treating cancer, these include Chemotherapy, Radio-
therapy, Hormonal therapy, Immunotherapy, Stem-cell transplants and Adjuvant ther-
apy (Sudhakar, 2009). These therapies do not seem to fully work and one of their biggest
pitfalls is harming normal cells during treatment (PosthumaDeBoer et al., 2011). If can-
cer is detected in its early stages, it may be curable. However, in other cases where the
tumors can be removed or significantly reduced, the tumor(s) may later relapse depend-
ing on their classification and location (Rutqvist et al., 1984).
Researchers and doctors have sought a novel treatment called oncolytic virotherapy
(Kirn et al., 2001).It involves treatment via virus able to replicate and clear tumor cells
leaving normal ones healthy (Russell et al., 2012).
Exact timing of when oncolytic viruses were discovered is vague, however, in 1886, it
was "accidentally" noted that a woman suffering from leukemia was temporarily relieved
after contracting flu (Dock, 1904), . Her previously distended liver and spleen deflated
to their conventional proportions and the number of her white blood cells improved
significantly too. Around the same period, A male toddler suffering from lymphatic
leukemia was taken ill by varicella, which is a viral disease characteristic of a rash. As
was the case of the woman too, his leukocyte count also improved greatly. The century
that followed saw modern medicine facilitate improvement on this mode of treatment,
with Chinese regulators approving the first marketing of an oncolytic virus (adenovirus
H101) in November 2005 (Kelly and Russell, 2007).
Oncolytic virotherapy is an alternative mode of treatment which has triggered a lot of
clinical research (Kirn, 2001; Kirn et al., 2001; Lawler et al., 2017; Liu et al., 2007; Pol et al.,
2016). Mathematical modelling was also used to help understand this novel mode of
treatment (Bajzer et al., 2008; Crivelli et al., 2012; Dingli et al., 2006; Paiva et al., 2009).
Most models have considered the rate of infection as well as clearance (of the virus),
measure of cell death and burst size (amount of new viruses produced once a tumor cell
gets infected (Bajzer et al., 2008; Malinzi et al., 2017; Tian, 2011)) as the only key factors of
oncolytic viruses. In addition to the above, it is imperative to further take into account
a) how fast/slow the virus would replicate and b) how strong and/or fast the anti-viral
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immune response would be.
It is with this regard that some mathematical models have considered taking delays into
account. We have the intracellular delay, herein described as time taken from when the
virus binds to the tumor cell to the proliferation of more cells (Tian et al., 2016; Xu, 2011)
The other is the immune response delay which is modelled as time taken by the immune
system to invoke a suitable response once it recognises the virus-infected cells (Crivelli
et al., 2012; Prestwich et al., 2008; Timalsina et al., 2017; Wang et al., 2013)
Although delays have been individually modelled, as at this time, it’s the first attempt
at analysing the out-turn of both delays in tandem.
In this thesis, we table a mathematical model having a duet waiting period with our aim
being to find a trade-off between the two delays that would lead to tumor elimination
or control.
1.1.1 Thesis outline
We present this work in six chapters. For the opening chapter, we give an overview of
the history of cancer, current statistics and treatment methods and give insight on on-
colytic virotherapy. In chapter two, we delve into the literature review where we unpack
the different types of cancer and how they spread and expound on oncolytic virother-
apy. The third chapter contains some mathematical preliminaries on delay differential
equations needed for the analysis of the model with delays. We have an overview of
simple mathematical models which do not consider delays in the following chapter and
carry out their equilibria and stability. We also look at a previously simple analysed
model. For chapter five, we introduce delays, carry out some analysis for their equi-
libria as well as use the DDE23 solver to perfom simulations and present the results in
the same chapter. To wrap up the thesis, we discuss the findings as well as shortfalls of






In this chapter, we present a literature review of the burden of cancer; epidemiology of
cancer, its risk factors and treatment. A special focus will be given to oncolytic virother-
apy which consists of using viruses that are able to infect and destroy cancer cells while
keeping normal cells unharmed.
2.2 Literature review
Cancer is a huge life-threatening epidemic. Over the past two decades, mortality rates
from all cancers fell by 17% in those aged between 30 and 60 years while for septuage-
narians and older, the mortality rate rose by 0.4% (Danaei et al., 2005)
It is a name given to a group of similar diseases which come about by the non-stop
division and spread of some of the body cells and eventual spread into surrounding
tissues (National Cancer Institute, 2015).
Cancer can be grouped into five main categories each with characteristics unique to
their individual group. These include: Carcinomas - listed as the most prevalent type
of cancer such as prostate, breast, lung and colorectal cancers, they occur on the skin
and/or tissues lining internal organs and glands forming solid tumors; Sarcomas - these
develop in connective tissues such as: bones, cartilage, fat, muscles, nerves, tendons,
blood vessels and lymph vessels; Leukemia - these are a group of cancer cells in the
blood and/or bone marrow. It includes several types of leukaemia. Lymphomas are
4
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cancer cells that attack a body’s immune system starting from the lymphatic system
which mitigates infection. It is characterized by two types, namely, Hodgkin and non-
Hodgkin lymphomas; and lastly, Central nervous system cancers developing within
the brain and the spinal cord. (American Society of Clinical Oncology, 2018; Cancer
Centre, 2018)
While patients can suffer from a similar type of cancer such as leukaemia, cancer cells
may vary from one individual to another due to variations in their cell structure and
chemistry. Recent research has seen classification of cancer groups into sub-groups.
(Cancer Centre, 2018)
In a healthy individual, cells divide to form new ones. They later die when they become
old and damaged and consequently are replaced by new cells. In the unfortunate case
that this systematic order is disrupted or breaks down, the cells become abnormal and
survive instead of dying and new ones form where they aren’t required. This continu-
ous division may then form malignant growths called tumors. (National Cancer Institute,
2015)
Growth of tumors is attributed to the fact that cancer cells aren’t as specialized as nor-
mal cells and therefore not maturing into different cell types with individual functions,
which causes them to multiply at a faster than that of the neighbouring cells. Many
solid tumors are masses of tissues except in the case of blood cancer, known as leukemia,
which isn’t characterised by solid tumors. (National Cancer Institute, 2015)
However, extensive research over the last century suggests that solid tumors do not
necessarily lead to death, but metastasis of the tumors do. Actually contributing 90% of
deaths in these types of cancers (Gupta and Massagué, 2006). Metastasis herein, refers
to a two-step process where firstly, the unstable cells attach themselves to a tissue far
from the initial growth (Gupta and Massagué, 2006), and later, these cells develop into
a new growth (Chaffer and Weinberg, 2011).
Cancerous tumors are dangerous since as they grow, they also destroy nearby cells. They
can also get transported all around the body, leading to the creation of new tumors
where they arrive (Alfano et al., 1993; Farnsworth et al., 2018). This spreading - metasta-
sis, earlier defined, is the main reason that the detection of cancer prior to spreading is
of high importance to minimise severity. Cancer cells are known as malignant while the
non-cancerous are known as benign. (Alfano et al., 1993)
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There are many types of cancers.(National Cancer Institute, 2015). Of these, only 5− 10%
are attributed to genetic defects. Environment and lifestyle choices including smoking,
poor diet, alcohol, radiation, pollution and infectious organisms among others, cause
the remaining 90− 95% cases. (Anand et al., 2008)
Depending on extent at first diagnosis, it’s grouped into stages ranging from 0− 4. These
stages help determine spread and best treatment method(s). Stage 0 is before the cancer
spreads. The cancerous cells have not migrated from the area they formed in. In stage 1,
the cancer has not spread tolymph nodes and other organs of the body, rather just a little
in neighbouring tissues only. Stage 2− 3 means that neighbouring tissues and lymph
nodes have been affected while the final stage 4, commonly referred to as metastatic/
advanced cancer means that the cancer has moved to other body parts. Leukaemia is
not staged as it spreads throughout the body. (American Cancer Society, 2018; Cancer
Institute NSW, 2015)
There are various ways to stage cancer all depending on where it is located. A doctor
may either carry out a physical examination or run imaging tests like scans. For results
confirmation, a biopsy, which is a medical procedure involving examining of tissue un-
der a microscope in this case to determine presence of cancer cells, is carried out. Most
staging is carried out via the TNM(Tumor, Node, Metastasis) system (Cancer Institute
NSW, 2015)
On a wider global scale, it is reported that about 6 years ago, there were about 14 million
cases reported and over 8 million deaths due to this disease. 57% of the cases occurred in
less developed regions such as Africa as well as 65% of death reports. Statistics indicate
that new reports each year will spring up to almost 24 million within the next decade.
(National Cancer Institute, 2015)
Further note that these regions are the home to over 80% of the world’s population.
This is mainly attributed to bad lifestyle choices which increase the risk of cancer like
cigarette smoking, lack of a proper diet or even changes in reproduction. (Torre et al.,
2015)
There are several different modes of treatment which can be offered to a cancer patient
depending on the type of cancer they are suffering from, its location and how advanced
it is.
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Cancer was regarded as an incurable disease until the 19th century when surgical re-
moval was made more efficient and available by use of anaesthesia and improved tech-
niques. Before 1950, surgery was the preferred means of treatment but after 1960, ra-
diation started being implemented as well. Over time however, neither surgery nor
radiation or a combination of the two as a means of treatment was adequate to con-
trol the metastatic cases of cancer. For better treatment and improved survival rate to be
achieved, it was then noted that therapy needed to reach all body parts since sometimes,
tumors have been reported as migrating to other parts of the body. That is why current
efforts to cure this epidemic are centred around use of drugs, biological molecules and
immune mediated therapies (Wu et al., 2006) .
Current cancer-mitigation methods are listed in the following paragraphs.
Chemotherapy, also called chemo, is when, drugs are administered to a patient. Research
on this form of therapy was started by Ehrlich around 1891 (Hawking, 1963).
This form of treatment either stops or slows down the growth of cancer cells which
consequently ensures that the tumor also either dies off completely, stops increasing in
size or slows down in terms of growth. It also helps to shrink the tumors that may
otherwise cause pain (National Cancer Institute, 2015).
Both the medical practitioner and patient need to carefully consider both the potential
risks and benefits of chemotherapy treatment as there is a list of substantial reactions
of this treatment. Conventionally, short-term side effects may include neuro and renal
toxicity; while long-term side effects may include complications at a later stage such as
pulmonary defects arising after the conclusion of appurtenant chemotherapy (Morgan
and Rubin, 1998). The drugs agents used in chemo, enhance the body’s immune response
to an antigen after initial treatment. Adjuvant chemotherapy is especially used to sup-
press secondary tumour formation. Side effects will depend on the type of drugs used,
its dosage and treatment period of patient. (Partridge et al., 2001).
Radiotherapy, uses high doses of radiation to enable tumor shrinkage and death of tu-
mor cells. Treatment may be administered either internally or externally. Internal ra-
diotherapy treatment, known as brachytherapy, involves having a radioactive implant
inserted in the body, in or near the tumor. (?). It also helps to treat other problems as-
sociated with the tumors for example trouble with breathing. One of the greatest disad-
vantages is that long and/or frequent exposure to radio waves may lead to the damage
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of otherwise healthy tissues (Anscher et al., 2003).
In surgery, the surgeons physically cut off the solid tumors. However, this method of
treatment cannot be used to treat leukemia patients as there is no solid mass to extract
or patients whose cancers have spread as it could be too risky for the patient and lower
the chances of survival. It also carries a high risk of pain and infection which could lead
to other complications (Lederman, 1981).
Immune-based treatment involves a biological form of treatment where the immune
system is helped to fight the cancerous cells on its own. It consists of either adoptive cell
transfer, cytokines, treatment vaccines, BCG or monoclonal antibodies. The downfall is
that it has however been linked to several skin reactions, infections and severe allergic
reactions(Reisacher and FAAOA).
Ligand-targeted therapy on the other hand, involves using the genes of a patient, their
proteins and cancer features to treat the cancer, it has two main difficulties when it comes
to implementation of the treatment. One is that cancer cells become resistant and two,
drugs for some targets are hard to design (Wu et al., 2006) .
Hormone/hormonal therapy either slows down or stops the growth of cancers sentient
to the endocrine like breast cancer. (Byar and Corle, 1988; Zelnak and Carthon, 2018).
Treatment involves withdrawing the growth stimulus either by slowing down the rate
at which hormones are generated or by obstructing the attachment of receptors and
ligands (Jones et al., 2004).
Stem cell transplants procedures aid in restoring blood-forming stem cells in patients
who have already gone through chemotherapy and radiotherapy. This treatment may
carry with it heavy bleeding and subsequently, a very high risk of infection. It is also
quite expensive (Reya et al., 2001).
Whilst these various treatments have been administered to patients over the years, they
are not 100% successful and therefore the need to sought a much better treatment method.
This search is what has led to interest in virotherapy.
Due to more advanced studies in genetic engineering from that time on and especially
in recent years, replication-competent viruses are now being used as a selective mode
of cancer therapy (Rajalakshmi and Ghosh, 2018; Ring, 2002). Viruses are known to
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have cytotoxic effects (can be toxic to cells). Advancements in science has aimed at
harnessing these effects to target cancer cells. This is because viral genomes are highly
versatile therefore easily modified by either selectively infecting or replicating in cancer
cells. The viruses herein referred, are known as Oncolytic Viruses (Berkey et al., 2017;
Chiocca, 2002). These viruses with tumor specificity date back to the 1950s and 1960s
as being experimentally researched on but there was very limited success which forced
researches to abandon their study within a decade. Recent advancement in science and
technology has seen the resurgence of their study and keen interest in their specificity to
liase only tumor cells leaving healthy cells unharmed. In 2005, Chinese regulators an-
nounced a market approval for the first ever oncolytic virus, which was the adenovirus
H101 (Garber, 2006; Kelly and Russell, 2007).
Viruses being developed include herpes simplex, adeno, Newcastle disease viruses,weasles
among others (Ring, 2002). Tests have been carried out in animal studies yielding en-
couraging results and consequently, some viruses are on clinical trials (Ring, 2002).
In as much as this new viral treatment approach has several potential attributes, it also
carries with it a number of other several potential disadvantages like tumor cells imper-
vious to viral treatment (Vähä-Koskela et al., 2007), all which need to be addressed (Kirn
and McCormick, 1996).
These viruses destroy the cancer tumor cells in two main ways :
a) by being directly cytolytic to the host tumor cells which in turn may lead to to
tumor remission (Wodarz, 2001) or
b) specific immune responces may be induced due to the presence of the virus lead-
ing to lysis of the tumor cells (Wodarz, 2001)
The agency for research on cancer (International agency for research on Cancer, 2018)
responsible of collecting worldwide data, highlights that cancer is a huge societal bur-
den and has become a major focus in finding ways on how best to mitigate this disease
listed among non-communicable diseases (NCDs)
According to the World Cancer Research Fund (World Cancer Research Foundation,
2018), in 2018, it was projected that the most common type of cancers worldwide were
lung and breast cancer, accounting for∼ 12.3% each of the total new diagnosed cases. In
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men, ∼ 44.4% of all cancers were lung, prostate and colorectal cancers and their preva-
lence was in the same order. In their female counterparts, the most common types in
order were breast, colorectal and lung cancers with breast cancer contributing ∼ 25.4%
of the overall ∼ 43.9%. All the cases excluded non-melanoma skin cancer. More clearly,
∼ 18 million cancer cases were diagnosed with 9.5 million cases reported in men and
the remaining 8.5 million in women.
2.3 Summary
Having discussed what cancer is, its causes, stages, treatment methods available as well
as the groups in which different cancer falls, we introduced the new realm of treatment
known as Oncolytic virotherapy where the normal cells are left unharmed.
Stellenbosch University https://scholar.sun.ac.za
Chapter 3
Preliminaries on Delay Differential
Equations
We table a few preliminary findings on delay differential equations from the book Erbe
(2017), that we need throughout this thesis.
3.0.1 Existence and Uniqueness Results
Let τ be a positive constant and denote by C = C([−τ, 0],Rn) the Banach space of con-
tinuous functions defined on the interval [−τ, 0] into Rn endowed with norm
‖ϕ‖ = sup
θ∈[−τ,0]
‖ϕ(θ)‖ , ϕ ∈ C
Let α be a real positive number and x an element of C([−τ, α],Rn) For all t ∈ [0, α], we
denote by xt the function (in C) defined by
xt(θ) = x(t + θ), θ ∈ [−τ, 0].
Let f be a function defined on an open subset Ω of C with values in Rn and consider the
following delay differential equation:
d
dt
x(t) = f (xt), for all t ≥ 0 (3.0.1)
Definition 3.0.1. The function f : C → Rn is differentiable at φ, if there exists a linear function
Lφ such that
f (φ + ψ) = f (φ) + Lφ (ψ) + ε (‖ψ‖) ,
where ε satisfies the condition lim‖ψ‖→0
ε(‖ψ‖)
‖ψ‖ = 0
We denote Dϕ f (φ)ψ = Lφ (ψ) , where the subscript φ is omitted for notation convenience.
11
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Lemma 3.0.2. For each constant c ∈ [−τ, 0] , the function g : C → R defined by
g (φ) = φ (c)
is differentiable and
Dϕg (φ)ψ = ψ (c)
Proof. We have
g (φ + ψ)− g (φ) = (φ + ψ) (c)− φ (c) = φ (c) + ψ (c)− φ (c) = ψ (c) = ψ (c) .
Then
g (φ + ψ) = g (φ) + ψ (c)
which we write as
g (φ + ψ) = g (φ) + Lφ (ψ) + ε (‖ψ‖)
where Lφ (ψ) = ψ (c) and ε (‖ψ‖) = 0 which satisfies lim‖ψ‖→0
ε(‖ψ‖)
‖ψ‖ = 0
Hence Dϕg (φ)ψ = ψ (c)
Using the lemma above and the product rule for derivatives we obtain the following
lemma:






g (φ) = φ1 (c) φ2 (c)
is differentiable and
Dϕg (φ)ψ = ψ1 (c) φ2 (c) + φ1 (c)ψ2 (c) .
Proof. We have
g (φ + ψ)− g (φ) = (φ1 + ψ1) (c) (φ2 + ψ2) (c)− φ1 (c) φ2 (c)
= φ1 (c)ψ2 (c) + ψ1 (c) φ2 (c) + ψ1 (c)ψ2 (c) ,
which we write as
g (φ + ψ) = g (φ) + Lφ (ψ) + ε (‖ψ‖)
where









Dϕg (φ)ψ = φ1 (c)ψ2 (c) + ψ1 (c) φ2 (c)
Definition 3.0.4. Let ϕ be an element of C. A function x is a solution of equation (3.0.1) with
initial value ϕ at t = 0, if there exists a constant α > 0 such that:
i. x is defined and continuous on the interval [−τ, α];
ii. x0 = ϕ;
iii. x is differentiable on [0, α] and satisfies the equation (3.0.1) for all t ∈ [0, α].
The following theorem guaranties the existence and uniqueness of solutions for equa-
tion (3.0.1):
Theorem 3.0.5. Let Ω be an open subset of C and f be a function defined on an open subset
Ω. If f is continuous, then equation (3.0.1) has for each element ϕ in C, at least one solution
with initial condition ϕ. If, in addition, the function f is locally Lipschitzian, then the solution
is unique.
For the global existence of solutions we refer to the following proposition:
Theorem 3.0.6. Assume that for some constants c1, c2 ≥ 0 the function f is continuous and
satisfies the condition
‖ f (ϕ)‖ ≤ c1 ‖ϕ‖+ c2, ϕ ∈ C.
Then, for all ϕ in C, the solution of equation (3.0.1) with initial condition ϕ is defined on the
entire interval [−τ,+∞].
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3.0.2 Equilibria and Stability
Consider the following linear equation
d
dt
x(t) = Lxt, (3.0.2)
where L is a continuous linear operator from C into Rn.
Definition 3.0.7. The characteristic equation associated with equation (3.0.2) is obtained by
exploring solutions of (3.0.2) of the form x (t) = ezt. It is given by
det ∆(z) = 0, (3.0.3)






and ez. In being the function defined by:






In the remainder of this chapter we drop the subscripts and denote both In×n and In by
I.
Theorem 3.0.8. 1. If all the roots of (3.0.3) have negative real parts, then the trivial solution
x ≡ 0 for equation (3.0.2) is exponentially asymptotically stable.
2. If at least one of the roots of (3.0.3) has a positive real part, then x ≡ 0 is unstable.
Consider the ’semi-linear’ equation
d
dt
x(t) = Lxt + F(xt), (3.0.4)
where F is continuously differentiable on C with values in Rn such that F(0) = 0 and
DϕF(0) = 0. The characteristic equation of (3.0.4) at x ≡ 0 is given by




Theorem 3.0.9. 1. If all the roots of (3.0.5) have negative real parts, then the equilibrium
solution x ≡ 0 for equation (3.0.4) is asymptotically stable.
2. If at least one of the roots of (3.0.5) has a positive real part, then x ≡ 0 is unstable.
Assume now that equation (3.0.1) has an equilibrium point, x∗, i.e. f (x∗) = 0, and that
f is continuously differentiable. The characteristic equation of (3.0.4) at x∗ is given by
det (zI − L(ez. I)) = 0, (3.0.6)
where L (ψ) = Dϕ f (x∗)ψ.
By a simple change of variable, y (t) = x (t)− x∗, which shifts the equilibrium point x∗
to 0, we deduce from Theorem (3.0.9) the following result:
Theorem 3.0.10. 1. If all the roots of (3.0.6) have negative real parts, it follows that the
equilibrium solution x ≡ x∗ for equation (3.0.1) is asymptotically stable.
2. If at least one of the roots of (3.0.6) has a positive real part, then x ≡ x∗ is unstable.
3.0.2.1 Example 1
Consider the following equation:
dx
dt
= ax (t) + bx (t− τ)
Using the shift notation yt (θ) = y (t + θ) , the above equation becomes
dx
dt
= axt (0) + bxt (−τ)




where f : C = C ([−τ, 0] ,R)→ R is defined by
f (φ) = aφ (0) + bφ (−τ) .
Using Lemma 3.0.2, we deduce that the derivative of the function f (φ) = aφ (0) +
bφ (−τ) at φ is given by
Lψ = Dϕ f (φ)ψ = aψ (0) + bψ (−τ) .
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The characteristic equation is given by
det (zI − L (ez. I)) = 0
that is
z− a (ez. I) (0)− b (ez. I) (−τ) = 0
z− a− be−zτ = 0
3.0.2.2 Example 2
Consider the following basic model for virotherapy
dS
dt
= λ− dS− βSV
dI
dt
= βSV − δI
dV
dt
= NδI − cV.
(3.0.7)
Full details of the meaning and assumptions of this model are presented in Chapter 3.
Introducing a constant delay τ (accounting for the duration of time required for replica-
tion of infected cells), we obtain the following model
dS
dt
= λ− dS− βSV
dI
dt
= βS (t− τ)V (t− τ)− δI
dV
dt
= NδI − cV
(3.0.8)
To study this model we first write it into the standard from (3.0.1).




and let x (t) =
 S (t)I (t)
V (t)




 λ− dx1 (t)− βx1 (t) x3 (t)βx1 (t− τ) x3 (t− τ)− δx2 (t)
Nδx2 (t)− cx3 (t)





 λ− dxt1 (0)− βxt1 (0) xt3 (0)βxt1 (−τ) xt3 (−τ)− δxt2 (0)












→ R3 is given by
f (φ) =
 λ− dφ1 (0)− βφ1 (0) φ3 (0)βφ1 (−τ) φ3 (−τ)− δφ2 (0)
Nδφ2 (0)− cφ3 (0)

Lemma 3.0.11. The characteristic equation of model (3.0.8) at an equilibrium point E = (S, I, V)
is given by
χE = det
−d− βV − z −rkS −βSβe−zτ1V −δ− z βe−zτ1 S
0 p −c− z
 = 0
Proof. The characteristic equation of model (3.0.8) at E = (S, I, V) is given by
det (zI − L(ez. I)) = 0,
where L (ψ) = Dϕ f (E)ψ is calculated using Lemmas (3.0.2) and (3.0.3). We obtain
D f (E) φ =
 −dφ1 (0)− βφ1 (0)V 0 −βSφ3 (0)βφ1 (−τ)V −δφ2 (0) βSφ3 (−τ)
0 Nδφ2 (0) −cφ3 (0)

Then
D f (E) (ez. I) =




det(zI − L(ez I)) =
 z + d + βV 0 βS−βe−zτ1V z + δ −βSe−zτ1




Overview of simple mathematical
models of tumor virotherapy
4.1 Introduction
We now assess some basic models of tumor oncolytic virotherapy (Russell et al., 2012),(Liu
et al., 2007) and (Vile et al., 2002), followed by a preliminary analysis of their qualitative
properties. We further carry out mathematical analysis of their equilibria and apply the
next generation matrix determining the reproductive number R0 and later analyse the
sensitivity indices. We end the chapter by a discussion of a model by (Bajzer et al., 2008)
4.2 Overview of a simple virotherapy model
A simple representation of models proposed in (Russell et al., 2012),(Liu et al., 2007),(Vile
et al., 2002) and (Bajzer et al., 2008) can be formulated as follows
dS
dt
= λ− dS− βSV
dI
dt
= βSV − δI
dV
dt
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Figure 4.1: Basic Viral Infection Model
Here S represents uninfected tumor cells which are assumed to grow at a constant rate
λ, then either die with a per capita constant rate d or get infected with oncolytic virus at
a constant rate β.
Cells that have been infected, I, perish via natural process or when they burst at a con-
stant rate δ (higher than that of the uninfected cells i.e. δ > d). We presume the (natural)
death rate is negligible in contrast to the bursting rate and therefore, throughout this
thesis, we will refer to the latter as the death rate. Tumor cells that burst produce N
viruses which will either be cleared at a rate c or proceed to infect other cells within the
population. (Dingli et al., 2006)
In the investigation of the oncolytic effect, the key parameters we will be keenly looking
at include the infection rate β, the life span of the contaminated cells δ, in addition to the
rate at which the virus is cleared, c and the burst size N. We need to figure out which
among these parameters is key in increasing and perhaps maximizing the effect of the
oncolytic viruses. β would be of importance since the oncolytic viruses are capable
of infecting a large number of tumor cells. N is also important because tumor cells
that are infected with oncolytic viruses have a high number of infected cases spawned
from each infected case. Clearance rate c is also key because once the viruses have been
intravenously introduced into the host, they need to atleast live until they reach the
target cells and not die immediately due to a harsh environment. Even when produced,
they manage to infect some cells and then consequently those cells manage to produce
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some viruses N.
In the next subsection, we will calculate the basic reproductive number (R0) which
summarises the combined effect of the above parameters on viral replication and con-
sequently, tumor reduction. We will calculate R0 and investigate its sensitivity with
respect to these parameters.
The basic reproduction number has been used in epidemiology at population level for
diseases such as TB (Blower et al., 1995) and HIV (Ribeiro et al., 2010) as well as within
host models with cellular growth. (Hassell and May, 1973; Li and Shu, 2010). Typically,
we witness an outbreak of an epidemic when R0 > 1, whereas the illness may wash
away should R0 < 1. Consequently, the value of the reproductive number would thus
be crucial in determining how to slow down the effects of an epidemic or further to
entirely suppress an infection in a given population.
We note here that models of this type have been studied to model the interaction be-
tween HIV and the immunity whereby S would be the T-cells population; I the number
of adequately infected cells and V is the number of loose virus (Chun et al., 1997; Nowak
and Bangham, 1996; Rouzine and Weinberger, 2013; Stafford et al., 2000; Tuckwell and
Shipman, 2011)
We calculate the basic reproductive number (R0) which is detailed as the average amount
of secondary (viral) infection emerging from one infected (tumor) cell in a completely
vulnerable population during its whole infectious span.
4.2.1 Next Generation Method
The next generation technique was introduced by Van den Driessche and Watmough
(Van den Driessche and Watmough, 2002) to calculate the basic reproductive number. A
brief description of this method is as follows:
Assume that a population x = (x1, · · · , xn) that is subject to a disease is modelled by
this system of ordinary differential equations
dxi
dt
= Fi(x)− Vi(x), i = 1, · · · , n
where xi, i = 1, ..., m represent the infected population, while xi, i = m+ 1, ..., n represent
individuals susceptible to infection. Fi(x) is the frequency of occurrence of newer infec-
tions within compartment i and Vi (x) = V−i (x)− V
+
i (x) with V
+
i (x) (resp. V
−
i (x)) as
the occurrence of new entities into (resp. out of) partition i by other means.
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We further assume that the disease-free state set, denoted by Xs, is non-empty and that
the three functions Fi,V−i and V
+
i are presumed to be continuously differentiable and
satisfy the list below:
1. If x ≥ 0, then Fi, V+i , V
−
i ≥ 0 for i = 1, ..., n.
2. If xi = 0, then V−i = 0, particularly, if x ∈ Xs, then, V
−
i = 0 for i = 1, ..., m.
3. Fi = 0 if i > m.
4. If x ∈ Xs, then, Fi(x) = 0 and V+i (x) = 0 for i = 1, ..., m.
We further assume that the model has an asymptotically stable disease-free equi-
librium x0.
5. If FF (x) is fixed at null, then all the eigenvalues of DF (x0) have non-positive real
parts.





where ρ (M) is the spectral radius of the matrix M, that is, max
z∈σ(M)
|z| where σ (M) is the
set of all eigenvalues of M.
The matrix
M = DF (x0) [DV(x0)]−1
is called the next generation matrix.
Concerning model (4.2.1), we first sort the equations so that the first equations are for
the infected classes, obtaining 
dI
dt
= βSV − δI
dV
dt
= NδI − cV
dS
dt
= λ− dS− βSV
The disease-free equilibrium of the (sorted) model is given by x0 = (0, 0, S0) , where





and that of other transfers is given
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(where S0 is the initial tumor size)


















4.2.2 Sensitivity Index ofR0
In general, sensitivity analysis can be used to measure different reaction of precari-
ousness of the loaded parameters of a model and subsequently, the effect(s) on the
model’s output. This basically means that sensitivity analysis of a model may show-
case how much input variability there is which may consequently cause variations in
the model products. In other words, the main motive of this analysis is to quantify this
input-output relationship. This analysis may be applied in refining mathematical mod-
els through quantitatively showcasing major features and methods that can sometimes
steer towards identifying approaches to be used for lowering the prospect of disease
spread in a population, in our case, tumor cells population. (Arriola and Hyman, 2009)
SinceR0 depends on factors such as timespan of infection, rate of infecting a susceptible
cell as well as the quantity of new viruses induced by an infected cell 1% variations in
different parameters may therefore cause different variations inR0.
In this section, we seek to find out how sensitive R0 is to some of the model’s param-
eters, this will further show the relative significance of the parameters on the model
forecasts herewith.
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Generally, sensitivity index is defined as the proportion of the relative change in a given
variable to that in the parameter (Chitnis et al., 2013). We may use partial derivatives to
compute it when the variable is a differentiable function of the parameter .













This implies that when ∆pp = 1%, then
∆ξ
ξ ≈ α%. This means that a proportional increase
of 1% in p, translates to an increase of α% in ξ (α may be positive or negative).

















We can now deduce that the reproductive number, R0, is sensitive in absolute value,
equally to all parameters β, c and N. In fact 1% decrease in c (resp. increase in β or N)
will lead to 1% increase (resp. decrease) inR0. Our aim is to increaseR0. We can achieve
this either by increasing β or N or by decreasing c.
Calculating R0 and assessing its sensitivity is useful in informing us if viral infection
will persist or die out, however, it does not inform us on the transient and equilibrium
stages and how sensitive they are to the relevant parameters. Therefore, we seek in
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the next section to calculate the equilibrium points and investigate their sensitivity to
the key virus parameters. Numerical simulations can be performed to investigate the
intermediate stages and confirm the mathematical findings. This will be done for the
more general model that we will be dealing with in Chapter 5.
4.2.3 Equilibrium points and stability
We evaluate the system below to achieve the equilibrium points
λ− dS− βSV = 0
βSV − δI = 0
NδI − cV = 0
(4.2.2)







Hence V = 0, leading the virus free equilibrium VFE =
(
λ
d , 0, 0
)
, or S = cNβ , leading the






























VIE is biologically feasible if and only if R0 > 1, in the next theorem, we establish its
stability properties.
Theorem 4.2.3. WhenR0 < 1, VFE is the model’s (4.2.1) sole equilibrium point and is locally
asymptotically stable. When R0 > 1, VFE becomes not stable and VIE exists and is locally
asymptotically stable.
Proof. Existence of equilibrium points has already been discussed in the beginning of
this section. The stability properties of an equilibrium point E = (S, I, V) are found
from the Jacobian matrix through calculation of eigenvalues
JE =
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• At VFE, we have
JVFE =






whose eigenvalues are awarded by roots of the characteristic polynomial
(X + d)
(
X2 + X (δ + c) + cδ (1−R0)
)
= 0.
Hence VFE is locally asymptotically stable if and only ifR0 < 1.
• At VIE, we have
JVIE =




χ = X3 + A2X2 + A1X + A0
where
A0 = δ (cd + Vcβ− NSdβ)
A1 = (δ (d + Vβ) + c (d + δ + Vβ)− NSβδ)
A2 = (c + d + δ + Vβ) .
Since S = cNβ , then
A0 = δcβV
A1 = δ (d + Vβ) + c (d + δ + Vβ)− cδ = (c + δ) (d + Vβ) .
IfR0 > 1, then V > 0 implying that A0, A1 and A1 are all positive. Moreover,
A1 A2 − A0 = (c + δ) (d + Vβ) (c + d + δ + Vβ)− δcβV > 0.
Then by Routh-Hurwitz criterion all roots of the characteristic polynomial χ have
negative real parts, implying the VIE is locally asymptotically stable.
Next, we investigate how/if virotherapy helps reduce the Total Tumor Size at the virus
infected equilibrium. TTS is given by
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calculated from adding both the uninfected and infected tumor populations from the
VIE.
Proposition 4.2.4. IfR0 > 1 then TTS < S0 if and only if δ > d.























Hence, the reduction in tumor size is given by




































Thus, TTS < S0 if and only if R0 > 1 and δ > d.
The proposition above clearly shows that virotherapy helps reduce the total tumor size
(at equilibrium) as long as the oncolytic virus used has a basic reproductive number that
is higher than one and induces a mortality rate (of cells that have been infected) which
is greater than that of those uninfected (δ > d).
Noting the expression R0 = βλNcd does not involve infected tumor cells’ mortality rate δ
(which is substantially higher than speed of mortality of uninfected cancerous cells), we
deduce that one can increase the oncolytic effect in two independent ways:






27 4.2. Overview of a simple virotherapy model
Figure 4.2: Bifurcation Diagram 1
2. Alternatively, one can also increaseR0, which (by the sensitivity index analysis of
R0 performed in the previous section) can be equally achieved by increasing β (or
N) or decreasing c (λ and d being tumor parameters are left fixed). By rewriting


















3. Tumor "elimination" would be achieved if we simultaneously increase δ and R0,
then the minimal tumor size achieved is 0.
See the bifurcation diagram above for a graphical interpretation of the above points.
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The proposition further shows how the proportional reduction in tumor size changes












Which demonstrates a proportional decrease in the total tumor size that is linear with
respect to 1R0 and/or
1
δ .
To investigate which of the of the virus parameters contributes most to the reduction
of the total tumor size, we perform in the next section, a sensitivity analysis of TTS in
respect of virus parameters and death rate of the contaminated cells.
4.2.4 Sensitivity index of the endemic equilibrium point















Using the programming software, SAGEMATH, we calculate the formula of the sensi-




cδ + λβN − dc
ΓcTTS =
c(δ− d)
cδ + λβN − dc
ΓNTTS =
c(d− δ)
cδ + λβN − dc
ΓβTTS =
c(d− δ)
cδ + λβN − dc
We note that ΓβTTS = Γ
N
TTS = −ΓcTTS which means in absolute values, all three parameters
have the same proportional effect on TTS.
Now we use parameter values from table (4.1) to evaluate the sensitivity index of TTS
with respect to δ and β.
We note that the value of λ can be derived from the relation λ = S0d. If we consider
a tumor of size 2cm in diameter which is roughly 108 cells, then using the value of
d = 0.001 given in Table 4.1, we obtain λ = 105. N is chosen to be equal to 3000.
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parameter definition value Source
r growth rate of uninfected tumor cells 2 ∗ 10−2 (Okamoto et al., 2014)
k carrying capacity 0.000467 (Mahasa et al., 2017)
δ death rate of uninfected tumor cells 118 (Malinzi et al., 2018)
γ virus elimination rate 2 ∗ 10−8 (Malinzi et al., 2018)
p virus production rate 0.001 (Mahasa et al., 2017)
c virus clearance rate 2.5 ∗ 10−2 (Friedman et al., 2006) (Paiva et al., 2009)
b death rate of immune cells 2 ∗ 10−2 (Mahasa et al., 2017)
β Infection rate 7 ∗ 10−10 (Mahasa et al., 2017)
d death rate of uninfected cells 0.001 (Mahasa et al., 2017)
α virus production rate 1 ∗ 10−4 (Malinzi et al., 2017)
Table 4.1: Definition of state variables model parameters
The sensitivity indices of the four parameters that we took more interest in as mentioned




Table 4.2: Sensitivity Index of the total size of tumor (at equilibrium) in respect of the
model parameters
From the Table (4.2), we can see that a 1% increase in δ, induces a 0.99934% reduction
in the tumor size, which is around 1500 times higher than the relative change obtained
from increasing β. This is a very interesting result as δ does not even appear in the
expression ofR0 so one would think that δ is not as relevant in tumor reduction.
While all this is good and well, the model does not account for anti-viral immune re-
sponse. In the next section, we investigate the effect of anti-viral immune response on
the virotherapy.
4.3 Basic model with immune response
We extended a model from the previous section by including a Cytolytic T- Lymphocytes
(CTLs) immune response to viral infection, as discussed in the literature review. The
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resulting model reads as follows:
d
dt
S(t) = λ− βSV − dS
d
dt
I(t) = βSV − δI − γIZ
d
dt
V(t) = NδI − cV
d
dt
Z(t) = αIZ− bZ
(4.3.1)
where
• Z represents the population of virus-specific immune cells
• γIZ represents the death rate of productively infected cells due to the response of
the immune
• αIZ represents the rate at which immune cells are produced
• b represents immune cells death rate
4.3.1 Equilibrium points and Stability
Once we set the right hand side of (4.3.1) to zero, we deduce the equilibrium points:

λ− βSV − dS = 0
βSV − δI − γIZ = 0
NδI − cV = 0
Z (αI − b) = 0
(4.3.2)
From (4.3.2)4, we get that




1. If Z = 0, then, by following the same steps as for the model without immune
response studied in the previous section, we obtain a virus-free equilibrium point
VFE = (S0, 0, 0, 0)








(R0 − 1) ,
d
β
(R0 − 1) , 0
)
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Note that VIE is biologically feasible if and only ifR0 > 1.









Substituting these two expressions back into (4.3.2)1 and (4.3.2)2, we obtain{













































1 + q bα




This gives us the interior equilibrium point
Ē =
 S0











1 + q bα
) (R0 −(1 + q b
α
))
For the interior equilibrium point to be biologically feasible, we must have the
following condition
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Theorem 4.3.1. 1. IfR0 < 1, the virus-free equilibrium point
VFE = (S0, 0, 0, 0)
is the only non-negative equilibrium point of (4.2.1) and it is locally asymptotically stable.
2. If 1 < R0 < 1 + q
b
α








(R0 − 1) ,
d
β
(R0 − 1) , 0
)
exists and is locally asymptotically stable.
3. R0 > 1 + q
b
α
, VFE and VIE are unstable and an interior equilibrium point
Ē =
 S0











1 + q bα
) (R0 −(1 + q b
α
)) , q := Nβδ
cd
exists and is locally asymptotically stable.
Proof. The existence of the equilibrium points has already been discussed in the begin-
ning of this section. The stability properties of an equilibrium point E = (S, I, V, Z) is
calculated via eigen values of the Jacobian. We have
JE =

−d− βV 0 −βS 0
βV −δ− γZ βS −γI
0 Nδ −c 0
0 αZ 0 αI − b

• At VFE, we have
JVFE =

−d 0 − βλd 0
0 −δ βλd 0
0 Nδ −c 0
0 0 0 −b

From roots of characteristic polynomial we acquire eigenvalues
(X + b) (X + d)
(
X2 + X (δ + c) + cδ (1−R0)
)
= 0.
Hence VFE is locally asymptotically stable if and only ifR0 < 1.
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(R0 − 1) ,
d
β




−d− βV 0 −βS 0
βV −δ βS −γI
0 Nδ −c 0
0 0 0 αI − b

with characteristic polynomial
ξ = (X− (αI − b)) χ,
where χ is the characteristic polynomial calculated in the previous section given
by
χ = X3 + A2X2 + A1X + A0
with
A0 = δ (cd + Vcβ− NSdβ)
A1 = (δ (d + Vβ) + c (d + δ + Vβ)− NSβδ)
A2 = (c + d + δ + Vβ) .
We have established in the previous section that if R0 > 1, then all roots of the
characteristic polynomial χ have negative real parts. Hence VIE is locally asymp-



























−d− β Nδbαc 0 −βS 0
β Nδbαc −δ− γZ βS −γ
b
α
0 Nδ −c 0




−d− dQ 0 −βS 0
dQ −δ− γZ βS −γ bα
0 Nδ −c 0
0 αZ 0 0

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Using Maple, we calculate the characteristic polynomial of this equation, we find
the following fourth order polynomial
ζ = B0X4 + B1X3 + B2X2 + B3X + B4,
where
B0 = 1,
B1 = (c + d + δ + Zγ + Qd, )
B2 = d
(
1 + q bα
)
(δ + Zγ) + cd
(
1 + q bα
)
+ c (δ + Zγ) + Zbγ− NβδS,
B3 = cdδ
(




bc + (bd + cd)
(





q bα + 1
)
.
The principal diagonal minors of the Hurwitz matrix associated with the polyno-
mial ζ are given by:
Bi, i = 0, ..., 4,
B1B2 − B0B3,
B1B2B3 − B21B4 − B0B23.
One can show that when R0 > 1 + q
b
α
the above principal diagonal minors are
positive which by Routh-Hurwitz criterion (DeJesus and Kaufman, 1987) imply
that all roots of ζ have negative real parts and therefore Ē is locally asymptotically
stable.
We note here that when the antiviral immune response exists, the condition R0 > 1 is
no longer sufficient for the viral infection to persist. In fact, the threshold for persistence
of the virus is higher than 1, we must have
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Figure 4.3: Bifurication Diagram 2
This bifurcation diagram 4.3 shows that without virotherapy, the total tumor size (TTS)
stabilizes at S0. The introduction of a "weak" virotherapy (R0 < 1) is incapable of reduc-
ing the TTS. However, when using an oncolytic virus with an "intermediate" reproduc-
tive number (1 < R0 < 1 + q bα ), the TTS decreases with higher values of R0) to reach a
minimum value of SO
1+q bα
((1− dδ ) +
d
δ ) > S0
d
δ at R0 = 1+ q
b
α . Beyond this value of R0, the
TTS remains constant. This suggests that there is no benefit of using oncolytic viruses
with a "high" reproductive number (R0 > 1 + q bα ) as this will not lead to any further
reduction in the TTS and may only cause some undesirable side-effects.
4.4 Review of the Bazjer model
We now look into an existing model analysed by Bazjer et al. in (Bajzer et al., 2008) who
studied the use of a measles virus for oncolytic virotherapy. The model proposed con-
sists of three differential equations representing two tumor populations which are un-
infected and infected respectively and the virus population. Upon contact of the tumor
with the measles virus, cells clump together forming synctia which is a multi-nucleated
cell (Zsak et al., 1992), that eventually dies. They also can reproduce new viruses mean-
ing more tumor cells get infected and the cycle continues throughout treatment.
The resulting model reads as follows:
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dy
dy
= ry[1− (y + x)ε/Kε]− kyv− ρxy (4.4.1)
dx
dx
= kyv− δx (4.4.2)
dv
dt
= αx−ωv− kyv (4.4.3)
• y is the population of uninfected cells where r depicts rate of growth; K the carry-
ing capacity and parameter ρ > 0 being the constant rate which describes fusion
of cells.
• x is the combined population of both infected cells and synctia dying at the rate
δ > 0.
• The virus population is denoted by v with α being the constant rate at which the
viruses are produced per day per cell; ω is the constant rate at which viruses die
and k is the rate of infection per day for every 106 cells or virons.
This model assumed that a tumor would be removed if the total tumor population is
one cell but this is not feasible biologically.
Parameter estimation and data fitting was done as well as the stability analysis. Lastly,
numerical simulations helped to determine conditions which favoured successful vi-
rotherapy and validate the model.
We extend this model by introducing an immune response and also extend their schematic
diagram to cater for the extension. Further on we discuss a simple virotherapy model
which again, includes tumor population as well as virus. The model is not novel and has
been adopted from other standard HIV and population dynamics models (Heuveline,
2003; Jenner et al., 2018; Phan and Tian, 2017). We calculate its equilibrium points, repro-
ductive number as well as the sensitivity index to get the most important parameter.
The extended model would be characterized as:
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dy
dt
= ry[1− (y + x)ε/Kε]− kyv− ρxy (4.4.4)
dx
dt
= kyv− δx (4.4.5)
dv
dt
= αx−ωv− kyv (4.4.6)
dz
dt
= cxz− bz (4.4.7)
Figure 4.4: Basic Viral Infection Model with Proliferation of Uninfected Cells
In this extended model, the new population z is that of the immune cells where the
parameter c is the proliferation rate due to the infected tumor cells x, and b is the death
rate.
We can schematically model this as seen below where the solid arrows depict the pop-
ulation growth/influx and the dotted lines are indicative of the dependency of corre-
sponding rates on the population of uninfected cells x.
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Figure 4.5: Schematic representation of tumor-cell-immune interaction (Bajzer et al.,
2008)
4.5 Summary
We considered and analysed the first two models mathematically taking into account a
constant tumor growth rate λ, which was extended by (Bajzer et al., 2008) to a logistic
proliferation rate. (The mathematical analysis of the latter was not carried out as it will
be done for a more general case). All these models focus on the oncolytic potency of
the virus R0 and the strength of the immune response bα , but don’t account either for
the speed of viral replication and/or the speed at which the immune system responds.
In the next chapter, we introduce a model with a non-constant proliferation rate that in-





In the previous chapter we considered an ODE based model of virotherapy. However,
for some tumors, oncolytic viruses can only be administered intravenously as direct
viral injections can be harmful. However, this method of introducing the viruses into
the host’s system, poses a big challenge with virus delivery as the virus becomes more
prone to the immune response (Kirn et al., 2001). The success of such treatment depends
on, among other factors, how quick the viral replication is and how slow is the antiviral
immune response is.
Delays involved are:
1. Immune response delay: modelled as time delay for immune system to develop
suitable response once it recognizes virus-infected cells (Prestwich et al., 2008;
Timalsina et al., 2017) and
2. Intracellular delay: modelled as the time between attachment of a virus to a cell
and the production of new viruses. (Tian et al., 2016; Xu, 2011).
We are interested in the effects that these delays may have on the overall effect of on-
colytic virotherapy. Faster viral replication often leads to higher oncolytic effects and
hence tumor reduction, while faster antiviral immune responses hinder viral replica-
tion leading to tumor growth. We aim in this chapter to find a trade-off between these
two delays that optimizes oncolytic virotherapy. We note here that the modelling of
39
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the simultaneous effect of two delays in oncolytic virotherapy has not been addressed
previously.
5.1 Basic model with logistic growth
The model that we consider in this section is an extension of the basic model without
immune response considered in the previous chapter by considering a logistic growth
for the tumor population. The resulting model reads as follows:
dS
dt
= rS(1− k(S + I))− βSV − dS
dI
dt
= βSV − δI
dV
dt
= pI − cV
where
• S(t): Uninfected tumor cells
• I(t): Productively infected tumor cells (meaning that they are specifically those
that are able to produce viruses)
• V(t): Population of oncolytic viruses
• r: Logistic proliferation rate of tumor cells that aren’t infected
• 1k : Total volume of uninfected tumor cells
• βSV: Infection rate of the uninfected tumor cells
• d: Per capita death rate of uninfected tumor cells
• δ: Per capita death rate (due to lysis) of productively infected cells
• pI(t): Production rate of the oncolytic viruses by productively infected cells
• c: Clearance rate of oncolytic viruses
As in the prior chapter, we’ll analyse the model’s reproductive number, equilibria and
their stability properties.
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5.1.1 Reproductive number (R0)
Before applying the next generation method to calculate R0, we note that due to the
logistic proliferation rate, the model exhibits two virus-free equilibrium points as estab-
lished in the following proposition. Therefore, it is key to choose the right disease-free
equilibrium point in our implementation of the next generation method. In fact, when
there is no virus, the model simplifies to the following scalar equation
dS
dt
= rS(1− kS)− dS (5.1.1)
which has the following stability properties:
Proposition 5.1.1. 1. If r < d then model (5.1.1) has only one non-negative equilibrium
point Θ = 0. Moreover, Θ is locally asymptotically stable.
2. If r > d, then Θ is unstable and (5.1.1) has an additional non-negative equilibrium point,
S0 = r−drk , that is locally asymptotically stable.
Proof. The existence of the (virus-free) equilibrium points is obvious, their stability can




(rS(1− kS)− dS) = r− d− 2Skr.
• At S = 0, we obtain J0 = r− d. Hence, Θ is locally asymptotically stable if r < d
and unstable if r > d.
• At S0 = r−drk , we obtain JS0 = d − r. Hence, S0 is locally asymptotically stable if
r > d and unstable if r < d.
Remark 5.1.2. We note that the equation (5.1.1) can be solved explicitly, making the (local)
stability results global.
Based on the above proposition, we see that when r < d, there is no tumor cells and
therefore we do not need to perform any virotherapy. We therefore focus for the remain-
der of this chapter on the case r > d, which makes the model stabilize at the (virus-free)
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equilibrium point S0 = r−drk . It is at this equilibrium that we deduce the basic reproduc-
tive number of (5.2.1).
Commencing by sorting the equations of model (5.1) so that the first equations are for
the infected classes, we obtain
dI
dt
= βSV − δI
dV
dt
= pI − cV
dS
dt
= rS (1− k (S + I))− βSV − dS
The disease free equilibrium of this model is given by x0 = (0, 0, S0) , the rate of new





















































We note that R0 > 0 because we assume that r > d.
5.1.2 Equilibrium points and stability
From positive solutions of the following system, we deduce equilibrium points.







V = pc I
(5.1.2)
From (5.1.2)2, we have I = 0 or S = δcpβ .
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1. If I = 0, then by (5.1.2)3 we have V = 0 which, together with (5.1.2)1 , lead to S = 0
or S = r−drk .
In the first case, we obtain the trivial equilibrium point
Θ = (0, 0, 0) .







2. If S = δcpβ , then by substituting this expression along with (5.1.2)3 into (5.1.2)1 and
solving for I, we obtain
I =
δc2rk




























(R0 − 1) .














It’s of great significance to note that VIE is biologically feasible only whenR0 > 1.
We have the following proposition:
Proposition 5.1.3. 1. If r < d, then model (5.1) has only one non-negative equilibrium
point
Θ = (0, 0, 0)
which is locally asymptotically stable.
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a) IfR0 < 1, then VFE is locally asymptotically stable.














is non-negative and is locally asymptotically stable.
That is the model exhibits a transcritical bifurcation atR0 = 1.
Proof. The existence of these equilibria being already established, we restrict the proof to
the stability results which can be deduced from the eigenvalues of the Jacobian matrix:
JE =
r− d− 2rkS− rkI − βV −rkS −βSβV −δ βS
0 p −c
 .
1. At the trivial equilibrium point Θ, we have
JΘ =
r− d 0 00 −δ 0
0 p −c

whose eigenvalues include r− d,−δ as well as −c. Hence Θ is locally asymptoti-
cally stable.
2. At the virus-free equilibrium point VFE, we have
JVFE =
d− r d− r −β
r−d
rk
0 −δ β r−drk
0 p −c

which has the following characteristic polynomial:
(X− (r− d))
(
X2 + (δ + c) X + cδ (1−R0)
)
Hence by the Routh-Hurwitz criterion, VFE that’s locally asymptotically stable
when r < d andR0 < 1 and is unstable if r > d orR0 > 1.
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3. At the virus-infected equilibrium point VIE, we have
JVIE =
r− d− 2rkS− rkI − βV −rkS −βSβV −δ βS
0 p −c

Using (5.1.2)1 and the fact that S 6= 0, we obtain r− d− rkS− rkI− βV = 0. Hence
the first entry of JVIE reduces to
r− d− 2rkS− rkI − βV = −rkS.
Thus the Jacobian matrix reduces to
JVIE =
−rkS −rkS −βSβV −δ βS
0 p −c

which has the following characteristic polynomial:
ψ = X3 + A2X2 + A1X + A0
where
A2 = c + δ + Skr > 0
A1 = cδ− Spβ + cSkr + Skrδ + SVkrβ
A0 = S ((pβ + ckr) βV + ckrδ− kprβS)
Since S = δcpβ , then
A1 = Skr (c + δ + βV)
A0 = (pβ + ckr) βSV
Hence, ifR0 > 1, then V > 0 implying that A0 > 0 and A1 > 0. Moreover, we have
A1 A2 > A0, then by the Routh-Hurwitz criterion, VIE is locally asymptotically
stable if r < d and is unstable if r > d.
As done in the previous chapter for the model with constant tumor growth rate, we
investigate next how, in the case of logistic tumor growth rate, virotherapy reduces the







(R0 − 1) .
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Proposition 5.1.4. IfR0 > 1, then TTS < S0.
Proof. SinceR0 = βp(r−d)δcrk , then
TTS =










ckrδ− pβ (r− d)
kr (pβ + ckr)
.
SinceR0 > 1, then ckrδ− pβ (r− d) < 0 implying that TTS < S0.
Remark 5.1.5. Concerning the behaviour of TTS with respect to the virus parameters we deduce
from (5.1.5) that TTS is decreasing with respect to p and β, and increasing with respect to c and
δ.
For illustration purposes, we depict, in the next bifurcation diagram, the behaviour of TTS with
respect to β and δ. We first note that if other parameters are fixed, R0 > 1 if and only if β > βc :=
δcrk
p(r−d) ,
R0 > 1 if and only if δ < δc := βp(r−d)crk .
We also note that  TTS = S0 when β = βc :=
δcrk
p(r−d) ,
TTS→ 0 when β→ ∞.
and  TTS = S0 when δ = δc :=
βp(r−d)
crk ,
TTS = TTS0 :=
c(r−d)
pβ+ckr when δ = 0.
This leads to the following bifurcation diagrams
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Figure 5.1: Bifurcation diagram of TTS with respect to β
Figure 5.2: Bifurcation diagram of TTS with respect to δ
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5.2 Adding an intracellular delay
In this section, we extend model (5.1) by adding an intracellular delay to account for the




= rS(1− k(S + I))− βSV − dS,
dI
dt
= βe−dτ1 S (t− τ1)V (t− τ1)− δI,
dV
dt
= pI − cV,
(5.2.1)
where
• τ1: Time delay since infection for the infected cells to become productively infected
provided they survive this period
• e−dτ1 : Probability of survival of infected cells.
5.2.1 Reproductive number (R0)
It is important to note that the next generation method used to calculate R0 was devel-
oped only for ODE-based models. Therefore, in this section, we will calculate R0 by
means of the "intuition" method as described below:
Assume that at time t = 0, the model is at the disease-free equilibrium VFE = (S0, 0, 0, 0)
where S0 = r−dkd
a. One virus leads to e−dτ1 βS0 new infections per unit time, causing
e−dτ1 βS0
c new infec-
tions during its entire lifetime.
b. Each infected cell will produce p new viruses per unit time, leading to pδ new viruses
during its entire lifetime.
c. Hence each virus will lead to the production of e
−dτ1 pβS0
δc new viruses during its entire
lifetime.










whereR0 is the basic reproductive number of the model without delay.
5.2.2 Equilibrium points and stability
The equilibrium points are given by the positive solutions of the following system:







V = pc I
(5.2.2)
From (5.2.2)2, we have I = 0 or S = δcpβe−dτ1 .
1. If I = 0, then by (5.2.2)3 we have V = 0 which, together with (5.2.2)1, lead to S = 0
or S = r−drk .
In the first case, we obtain the trivial equilibrium point
Θ = (0, 0, 0) .








2. If S =
δc
pβe−dτ1
, then by solving (5.2.2)1 for I and substituting the expression S, we
obtain
I =





pβ (r− d)− ckrδedτ1
)
pβ (pβ + ckr)
=
c2krδedτ1 (Rτ1 − 1)
pβ (pβ + ckr)
.





ckrδedτ1 (Rτ1 − 1)
β (pβ + ckr)
.
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c2krδedτ1 (Rτ1 − 1)
pβ (pβ + ckr)
,
ckrδedτ1 (Rτ1 − 1)
β (pβ + ckr)
)
.
It is important to note that VIE is biologically feasible only when the reproductive
number is greater than one. We have the following proposition:
Proposition 5.2.1. 1. If r < d, then model (5.2.1) has only one non-negative equilibrium
point Θ = (0, 0, 0) which is locally asymptotically stable.
2. If r > d, then Θ becomes unstable and the virus-free equilibrium point VFE =
(
r−d
rk , 0, 0
)
is biologically feasible.
Moreover, VFE is locally asymptotically stable ifRτ1 < 1 and is unstable ifRτ1 > 1.
Proof. The existence of these equilibria being already established, we restrict the proof
to the stability results which can be deduced from the roots of the characteristic equation
χE = det
r− d− 2rkS− krI − βV − λ −rkS −βSβe−dτ1 e−λτ1V −δ− λ βe−dτ1 e−λτ1 S
0 p −c− λ

1. At the trivial equilibrium point Θ, we have
χΘ = det
r− d− λ 0 00 −δ− λ 0
0 p −c− λ

= − (λ + δ) (d− r + λ) (c + λ)
whose roots are r− d,−δ and−c. Hence Θ is locally asymptotically stable if r < d.
2. At the virus-free equilibrium point VFE, we have
χVFE = det
− (r− d)− λ −rkS0 −βS00 −δ− λ βe−dτ1 e−λτ1 S0
0 p −c− λ

= (d− r− λ)
(
λ2 + (δ + c) λ + cδ− pβS0e−dτ1 e−λτ1
)
= (d− r− λ)
(
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This is a transcendental equation involving the term e−λτ1 . The investigation of its
roots (not presented here) shows that VFE is locally asymptotically stable if and
only if r < d and Rτ1 < 1 and unstable if r > d orRτ1 > 1.
With regards to the VIE stability,
χVIE = det
r− d− 2rkS− krI − βV − λ −rkS −βSβe−dτ1 e−λτ1V −δ− λ βe−dτ1 e−λτ1 S
0 p −c− λ
 ,
using r− d− rkS− rkI − βV = 0, we obtain
χVIE = det
 −kS− λ −rkS −βSβe−dτ1 e−λτ1V −δ− λ βe−dτ1 e−λτ1 S
0 p −c− λ
 .
This gives another transendental equation
χVIE = −λ3 + A2λ2 + A1λ + A0
where
A2 = −c− δ− Sk
A1 = −
(




ckδS + (V (pβ + ckr)− kpS) βSe−dτ1 e−λτ1
)
.
The analysis of the roots of these characteristic equations is far off this thesis span. How-
ever, the numerical investigation suggests that VIE is unstable if r > d andRτ1 < 1.
Remark 5.2.2. SinceRτ1 = R0e−dτ1 , then:
1. IfR0 < 1, thenRτ1 < 1 for all τ1 > 0,
2. IfR0 > 1, thenRτ1 > 1 if and only if τ1 < τ1c := 1d lnR0.
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Thus, using the above remark, we re-write the proposition above in terms of τ1 to obtain
the following result:
Proposition 5.2.3. 1. If r < d, then model (5.2.1) has only one equilibrium point Θ =
(0, 0, 0) which is locally asymptotically stable.
2. If r > d, then Θ becomes unstable and the virus-free equilibrium point VFE =
(
r−d




a) ifR0 < 1, then VFE is locally asymptotically stable for all τ1.
b) ifR0 > 1, then the model exhibits a transcritical bifurcation at τ1 = τ1c, that is:
i. if τ1 > τ1c, then VFE is locally asymptotically stable
ii. if τ1 < τ1c, then VFE is unstable and VIE is biologically feasible.
This proposition shows that the condition R0 > 1 is not enough to sustain a viral
infection. In fact, in addition to this condition, the intracellular delay must be small
enough. In other words, for viral infection to persist, the virus has to have a high po-
tency (R0 > 1) and the viral replication must be fast enough (τ1 small enough).





c2krδedτ1 (Rτ1 − 1)
pβ (pβ + ckr)
.
Proposition 5.2.4. IfRτ1 > 1, then TTSτ1 < S0.
Proof. SinceRτ1 =











TTSτ1 − S0 =
c
(






ckrδedτ1 − pβ (r− d)
kr (pβ + ckr)
.
SinceRτ1 > 1, then ckrδ− βp (r− d) e−dτ1 < 0. Hence TTSτ1 < S0.
Stellenbosch University https://scholar.sun.ac.za
53 5.3. Mathematical Model with Immune Response





= S0 when τ1 = τ1c := 1d lnR0,
TTSτ1 = TTS when τ1 = 0,







(R0 − 1) .
The variation of TTS with respect to the virus parameters being discussed previously, we present
in the diagram below an illustration of the behaviour of TTSτ1 with respect to τ1.
Figure 5.3: Bifurcation diagram of TTSτ1 with respect to τ1
5.3 Mathematical Model with Immune Response
We extended the model considered in the previous section by (1) accounting for a Cy-
tolytic T- Lymphocites (CTLs) immune response as discussed in the literature review
and (2) including an immune reaction delay (Ong et al., 2007) (Yang et al., 2017).
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The resulting model reads as follows:
d
dt
S(t) = rS(1− k(S + I))− βSV − dS
d
dt
I(t) = βe−dτ1(S(t− τ1)V(t− τ1))− δI − γIZ
d
dt
V(t) = pI − cV
d
dt
Z(t) = αIZ− bZ
where
• Z(t): Population of virus-specific immune cells
• αIZ: Productively infected cells death rate due to immune response
• b: Death rate of immune cells.
Considering the rate of production rate of immune cells g, one can consider two types of
immune responses: α1 IZ = αe−δτ2 I(t− τ2)Z(t− τ2) or α2(It, Zt) := αe−δτ2 I(t− τ2)Z(t).




S(t) = rS(1− k(S + I))− βSV − dS
d
dt
I(t) = e−dτ1 βS (t− τ1)V (t− τ1)− δI − γIZ
d
dt
V(t) = pI − cV
d
dt
Z(t) = αe−δτ2 I(t− τ2)Z(t)− bZ
(5.3.1)
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Figure 5.4: Basic viral infection model with time delays
5.3.1 Equilibrium points
We note that, if r ≤ d then S(t) tends to zero as t tends to infinity, meaning that there
are no tumor cells to study or no therapy to consider. Consequently, in the remainder of
this section, we assume that r > d.
The equilibrium points of (5.3.1) are achieved by fixing its right hand side to null and

























From (5.3.2)4, we get that
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Solving (5.3.3)2 we obtain I = 0, or S = δce
dτ1
pβ .
a) If I = 0, then from equation (5.3.3)3 gives V = 0.Moreover, from (5.3.3)1, we
have S = 0 leading to the trivial equilibrium point
Θ = (0, 0, 0, 0)
or S = S0 =
r− d
rk
leading to the virus-free equilibrium
VFE = (S0, 0, 0, 0).
b) If S = δce
dτ1




)− (rk + pβ
c
)I = 0.

















(Rτ1 − 1) .








pβ (rkc + pβ)
(Rτ1 − 1) ,
rkδcedτ1
β (rkc + pβ)
(Rτ1 − 1) , 0
)
(5.3.4)
Note that VIE is biologically feasible if and only ifRτ1 ≥ 1.
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α = 0. But from (5.3.5)2 we






















where q := b(rkc+pβ)
αc(r−d) .






































































1− q bα eδτ2
)
> 1




eδτ2 < 1− 1Rτ1
.
Proposition 5.3.1. 1. If Rτ1 < 1 then, system (5.3.2) has two non-negative equilibrium
points: the trivial equilibrium point
Θ = (0, 0, 0, 0) ,
which is not stable, and the virus-free equilibrium point
VFE = (S0, 0, 0, 0)
which is locally asymptotically stable.
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2. IfRτ1 > 1 then, in addition to the trivial equilibrium point Θ and the VFE, system (5.3.2)







pβ (rkc + pβ)
(Rτ1 − 1) ,
rkcδedτ1
β (rkc + pβ)




a) If q bα e
δτ2 > 1− 1Rτ1 then (5.3.2) has three equilibrium points: Θ, VFE and VIE.
b) If q bα e
δτ2 < 1− 1Rτ1 , then, in addition to Θ, VFE and VIE, system (5.3.2) has an




























Proof. The existence of the equilibrium points was discussed in the beginning of this
section. The stability of Θ is determined by the roots of the characteristic equation
det

r− d− λ 0 0 0
0 −δ− λ 0 0
0 p −c− λ 0
0 0 0 −b− λ
 = 0,
with roots r − d,−δ,−c and −b. Hence Θ is locally asymptotically stable if and only
r < d.
The stability analysis of VFE, VIE and Ē involve more complicated transcendental equa-
tions and is therefore omitted. The simulations presented in the next section suggest
some stability results.
Remark 5.3.2. The condition q bα e
δτ2 < 1 − 1Rτ1 , that ensures the feasibility of the interior





















This shows that for an antiviral response to persist, the immune response must 1) be fast enough














), that is the produc-
tion rate of immune cells (α) is large enough compared to the death rate of immune cells (b).
Stellenbosch University https://scholar.sun.ac.za
59 5.3. Mathematical Model with Immune Response
Proposition 5.3.3. The interior equilibrium point Ē is biologically feasible if and only if


























, which is equivalent to
1
Rτ1





1− q bα eδτ2














Note that, τ1d < τ1c moreover, τ1d > 0 if and only if R0
(
1− q bα eδτ2
)








Using the above proposition, we deduce the following theorem that relates the models’
delays to the existence of equilibrium points.
Theorem 5.3.4. 1. If τ1 > τ1c then system (5.3.2) has exactly two equilibrium points: the
trivial equilibrium point
Θ = (0, 0, 0, 0)
which is unstable and the virus-free equilibrium and the virus-free equilibrium
VFE = (S0, 0, 0, 0) .
which is locally asymptotically stable.
2. If τ1 < τ1c then, in addition to the trivial equilibrium point Θ and the VFE, system (5.3.2)







pβ (rkc + pβ)
(Rτ1 − 1) ,
rkcδedτ1
β (rkc + pβ)
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a) If τ2 > τ2d, then (5.3.2) has three equilibrium points: Θ, VFE and VIE.
b) If τ2 < τ2d then τ1d > 0 and we have
i. τ1 > τ1d, then (5.3.2) has three equilibrium points: Θ, VFE and VIE.
ii. τ1 < τ1d, then, in addition to Θ, VFE and VIE, system (5.3.2) has an interior




























Concerning the total tumor size at equilibrium (denoted TTSτ1,τ2) we have the following
proposition:
Theorem 5.3.5. 1. If τ2 > τ2d, then
a) If τ1 > τ1c, then
TTSτ1,τ2 = S0.
b) If τ1 < τ1c, then





pβ (rkc + pβ)
(Rτ1 − 1)
2. If τ2 < τ2d then τ1d > 0 and we have
a) τ1 > τ1d, then





pβ (rkc + pβ)
(Rτ1 − 1)
b) τ1 < τ1d, then,










The results above are illustrated in the following bifurcation diagrams:
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Figure 5.5: Bifurcation diagram of TTSτ1,τ2 with respect to τ1 when τ2 > τ2d
Figure 5.6: Bifurcation diagram of TTSτ1,τ2 with respect to τ1 when τ2 < τ2d
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5.4 Model simulations
We used MATLAB DDE23 solver to perform our simulations and for the sake of these
simulations we use parameter values from table 4.1 and choose three values of τ1 :
1.1τ1c, 0.9τ1c, 0.09τ1c, we also choose two values of τ2 : 1.1τ2c, 0.1τ2c and two values of
b : 1.1bc, 0.9bc where bc =
1− 1R0
Q1
. This will ensure that we cover all the cases discussed in
Theorems 5.3.4 and 5.3.5.
We note that due to the long time the model takes to reach equilibrium, we chose our
initial conditions close enough to the model equilibrium points to ensure a fast conver-
gence of the model. While this choice is useful in "confirming" our mathematical finding,
it has the disadvantage that the model’s solutions do not deviate much from the initial
condition.
(a) Uninfected cells (b) Total Tumor Population
(c) Virus (d) Immune Response
Figure 5.7: Parameter values used for these figures are β = 4.077 ∗ 10−11, b = 8.197 with
R0 > 1 = 1.10, τ1 > τ1c
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Both the uninfected tumor population and that of the total tumor population exhibit a
similar behaviour. Although not sharp, we observe a decline at the onset of the treat-
ment sustained for about three months. Thereafter, the tumor cells begin to increase once
again to stabilize at the virus-free equilibrium point (S0, 0, 0, 0) which is locally asymp-
totically stable (5.3.4)1. We could attribute this to a strong immune response (which is
not the case as depicted by sub figure 1d). This only then leads us to conclude that a
strong and/or fast oncolytic effect are the contributing factors. We verify the strength
since the reproductive number,R0 > 1; but cannot say the same for the speed as τ1 > τ1c
which would in turn imply thatRτ1 < 1. The virus population also decreases over a few
years to reach the equilibrium. Also in line with theorem 5.3.4 (1), it is important to note
that the tumor size is at its lowest,that is, TTSτ1,τ2 = S0. (5.3.5)1a
(a) Uninfected cells (b) Total Tumor Population
(c) Virus (d) Immune Response
Figure 5.8: Parameter values used are β = 4.077 ∗ 10−11, b = 8.197 with R0 > 1 = 1.10,
τ1 < τ1c and τ2 > τ2c
We now observe that uninfected tumor cell population (2a) increases within the first
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100 days and stays roughly the same size for the next couple of years before eventually
shrinking down to the equilibrium. As for the total tumor population, treatment starts
before the tumor attains its maximum size and will only show its effect once the tumor
reaches a pseudo-steady state. The oncolytic effect of the virus only comes around after
so many years when the viruses start replicating but soon reach the equilibrium. The
virus-free equilibrium, VFE = (S0, 0, 0, 0) is locally asymptotically stable (5.3.4)2a and





pβ(rkc+pβ) (Rτ1 − 1) as
depicted by the Theorem (5.3.5)1b.
(a) Uninfected cells (b) Total Tumor Population
(c) Virus (d) Immune Response
Figure 5.9: Parameter values used include: β = 4.077 ∗ 10−11, b = 6.707 with R0 > 1 =
1.10, τ1 < τ1c, τ2 < τ2c and τ1 > τ1d
In this case, we note that τ1d > 0. The system 5.3.1, has a locally asymptotically sta-
ble virus-free equilibrium point VFE = (S0, 0, 0, 0) (5.3.4)2b. The uninfected tumor cell
population gradually increases over slightly more than three months and maintains the
size for the next couple of years before eventually shrinking down to the equilibrium.
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A similar trend is observed from the total tumor cell population graph (3b). Oncolytic
virotherapy does not commence until the tumor cannot grow any further and its effects
will only be observed at a pseudo-steady state. The immune cell population in 3d from
the diagram seems to be intersecting at the equilibrium at what may seem to be a zero
value due to the choice of our parameters but in the actual sense, it converges to a non-





pβ(rkc+pβ) (Rτ1 − 1).
(a) Uninfected cells (b) Total Tumor Population
(c) Virus (d) Immune Response
Figure 5.10: Parameter values used in this figure are β = 4.077 ∗ 10−11, b = 6.707 with
R0 > 1 = 1.10, τ1 < τ1c, τ2 < τ2c and τ1 < τ1d
We have a couple of equilibrium points for the system (5.3.1) at this point with the virus-
free equilibrium point VFE = (S0, 0, 0, 0) being locally asymptotically stable, the virus-
infected equilibrium point VIE = (( S0Rτ1
, rkδc
2edτ1
pβ(rkc+pβ) (Rτ1 − 1),
rkcδedτ1
β(rkc+pβ) (Rτ1 − 1), 0)) and










also stable. The total tumor size is, TTSτ1,τ2 = S0
(




α which is line with
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theorems (5.3.4)bii and (5.3.5)2b. The uninfected tumor cell population grows gradually
over three months before plateauing for the next several years to suddenly start quickly
dying off to the equilibrium. As for the immune response, the effect is minimal as it





We discuss the various findings both mathematically and analytically analysed and de-
tail our overall findings.
6.2 Discussion
For many years since the discovery of cancer, many treatment methods have been adopted
such as surgery, radiotherapy, chemotherapy among others. While these treatments
did relieve patients either of pain, tumor size reduction or both, they were not entirely
successful. One of their main disadvantages was affecting normal cells. Therefore, re-
searchers, doctors and scientists sought a better treatment method to relieve people of
this epidemic burden of cancer.
This was the birth of Oncolytic virotherapy. This treatment involves the intravenous
introduction of oncolytic viruses into tumors. Unlike the other modes of treatment,
the oncolytic viruses only affect the tumor cells and leave normal, healthy cells intact
making them a favourable mode of cancer treatment.
These viruses are fairly new anticancer agents, still under study and clinical trials. As
earlier mentioned, they were discovered by ’sheer luck’ when leukemia and Hodgkins
lymphoma patients suffered from influenza and hepatitis respectively. It was realized
that contracting these viral diseases had a direct influence on the shrinking of their tu-
mors and improvement of the patients’ white blood cell counts.
67
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More recently, studies have been focusing on the direct antitumor properties of the on-
colytic viruses. Even though there is mounting evidence that the host immune response
may be hinder the efficacy of oncolytic virotherapy as a cancer mitigation method, its
effect may be aided in a few ways such as through: inherent immune effectors, adaptive
antiviral immune responses which alienate infected cells or adaptive antitumor immune
responses.
Apart from the effects of reactions from the immune response, we looked at a simultane-
ous model of both immune response and intracellular delay. We sought to find a point
where we could effectively minimise the turnaround time of viral replication making
them speedily replicate while at the same time, trying to reach a point where the im-
mune response is slow enough not to attack the oncolytic viruses to help in achieving
optimum tumor cells reduction.
For simplicity, we assumed that the infection rate takes the mass action form rather than
other more complicated forms. Mass action is a fitting method of approximation as the
total population of tumor cells and oncolytic viruses remains fairly constant. Broadly,
it assumes that the contact rate grows intrinsically as the population of virons and cells
also grows, meaning, the density of the population is proportional to the total amount
of tumor cells and oncolytic viruses. (Crivelli et al., 2012) (Novozhilov et al., 2006)
We ran simulations with the help of the DDE23 MATLAB solver using parameters gath-
ered from literature review to substantiate these findings. Against a number of days, we
sought to analyse different populations: the uninfected tumor cell population, the total
tumor cell population which encompassed both the uninfected and infected tumor cells,
the viral population as well as the immune response.
The different set of graphs we got for each set of parameters confirmed our prior mathe-
matical findings where we could balance out the outcome of the immune system as well
as the replication time of the virus with treatment efficacy.
6.3 Conclusion
As seen in the calculations in chapter 4 and the graphs from chapter 5, we deduced
that patients can receive oncolytic virotherapy with optimum delay times of both the
immune reponse and the replication time of these viruses. In essence, for successful
treatment of cancer using this unworn method, one would need to make the immune
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response time (τ2) long enough which essentially translates to the immune system not
reacting too fast to the viruses hindering successful tumor reduction or total eradication
and concurrently, make the intracellular delay τ1 short enough. This would mean ensur-
ing that the virus used replicates at a very high speed in the tumor thus also positively
eliminating or shrinking the tumor in question.
We can arguably deduce that by taking time delays into consideration we may improve
the success rate of the treatment.
6.4 Future Work
This study did not take into account virus-rejecting tumor cells which has been high-
lighted in some articles as a hindrance from successful virotherapy. We also did not
input any data to validate our model. In future, we aim to use a more detailed and com-
plex model taking into account other things such as virus-tumor rejection and data to
better understand the role of time delays even further.
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